We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Mixed Results in PAC Trial

By HospiMedica staff writers
Posted on 11 Jan 2005
The results of a large clinical trial called ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) revealed no deaths related to the use of a pulmonary artery catheter (PAC) and no increase in hospitalizations but did suggest that a PAC should not be routinely used to guide therapy.

A PAC is a thin catheter inserted into a neck vein and passed through the right side of the heart into a pulmonary artery in order to measure pressures and flows from the right side of the heart and the lungs. More...
A tiny balloon is inflated to allow the measurement of pressures from the left side of the heart. A PAC is used in 3-5% of heart-failure patients who are hospitalized. Doctors also use a PAC to individualize medications for each patient and gauge their effects on heart function and symptoms.

ESCAPE involved 433 patients at 26 sites. The primary goal was to evaluate whether the increased precision offered by a PAC regarding heart and lung pressures results in improved patient survival and reduced time spent in the hospital over six months, compared with other therapies based on clinical assessment of physical signs and symptoms.

"We know that patients who received a PAC felt better, but then why didn't they have fewer deaths or hospitalizations?” asked principal investigator Dr. Lynne Stevenson, of Brigham and Women's Hospital (Boston, MA, USA). Dr. Stevenson believes the answer may lie in the fact that there was a big variation in how PAC information was used to treat patients. The researchers are conducting an in-depth analysis of the echocardiogram data in the trial, which may suggest some ways to adjust therapy without the risks of a PAC.


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Surgical Headlight
IsoTorch
LED Surgical Lamp
ACEMST35/57
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.